Literature DB >> 20350163

Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host.

Matthew J Memoli1, Rachel J Hrabal, Arash Hassantoufighi, Brett W Jagger, Zong-Mei Sheng, Maryna C Eichelberger, Jeffery K Taubenberger.   

Abstract

BACKGROUND: The overall impact of influenza virus infection in immunocompromised patients is largely unknown. Antigenic drift and genetic variations during prolonged influenza infection have been demonstrated. In this report we describe a multidrug-resistant H3N2 influenza virus isolated from an immunocompromised patient after 5 days of therapy.
METHODS: Multiple nasal wash samples were collected from an infected patient, and viral isolates were characterized. Sensitivity to antiviral agents was evaluated. Fitness and transmissibility were assessed in ferrets and tissue culture.
RESULTS: An in-frame 4-amino acid deletion emerged in the neuraminidase (NA) gene of an H3N2 virus after 5 days of oseltamivir therapy. No other changes in the NA or hemagglutinin genes were noted. Drug sensitivity assays revealed resistance to oseltamivir (>10-fold increase in 50% inhibitory concentration [IC(50)]) and reduction in sensitivity to zanamivir (3-7-fold increase in IC(50) or 50% effective concentration). No change in fitness or transmissibility was observed.
CONCLUSIONS: An in-frame NA gene deletion was rapidly selected for in an immunocompromised patient, resulting in decreased sensitivity of the isolate to available NA inhibitors without a change in fitness or transmissibility. This finding has implications for our understanding of the emergence of antiviral resistance and treatment of patients with influenza A infection, especially those who are immunocompromised.

Entities:  

Mesh:

Year:  2010        PMID: 20350163      PMCID: PMC2851491          DOI: 10.1086/651610

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community.

Authors:  P McMinn; A Carrello; C Cole; D Baker; A Hampson
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

2.  Influenza--WHO cares.

Authors:  Klaus Stöhr
Journal:  Lancet Infect Dis       Date:  2002-09       Impact factor: 25.071

3.  Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification.

Authors:  A E Krafft; K L Russell; A W Hawksworth; S McCall; M Irvine; L T Daum; J L Connoly; A H Reid; J C Gaydos; J K Taubenberger
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

4.  Influenza among hospitalized adults with leukemia.

Authors:  H M Yousuf; J Englund; R Couch; K Rolston; M Luna; J Goodrich; V Lewis; N Q Mirza; M Andreeff; C Koller; L Elting; G P Bodey; E Whimbey
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child.

Authors:  E Rocha; N J Cox; R A Black; M W Harmon; C J Harrison; A P Kendal
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.

Authors:  Rick A Bright; Marie-jo Medina; Xiyan Xu; Gilda Perez-Oronoz; Teresa R Wallis; Xiaohong M Davis; Laura Povinelli; Nancy J Cox; Alexander I Klimov
Journal:  Lancet       Date:  2005-09-22       Impact factor: 79.321

7.  Universal primer set for the full-length amplification of all influenza A viruses.

Authors:  E Hoffmann; J Stech; Y Guan; R G Webster; D R Perez
Journal:  Arch Virol       Date:  2001-12       Impact factor: 2.574

8.  Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.

Authors:  W Garrett Nichols; Katherine A Guthrie; Lawrence Corey; Michael Boeckh
Journal:  Clin Infect Dis       Date:  2004-10-11       Impact factor: 9.079

9.  Influenza in patients with human immunodeficiency virus infection.

Authors:  S Safrin; J D Rush; J Mills
Journal:  Chest       Date:  1990-07       Impact factor: 9.410

10.  Direct isolation of H1N2 recombinant virus from a throat swab of a patient simultaneously infected with H1N1 and H3N2 influenza A viruses.

Authors:  F Nishikawa; T Sugiyama
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

View more
  20 in total

1.  Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.

Authors:  Daisuke Tamura; Margaret Okomo-Adhiambo; Vasiliy P Mishin; Zhu Guo; Xiyan Xu; Julie Villanueva; Alicia M Fry; James Stevens; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.

Authors:  Matthew J Memoli; Rachel J Hrabal; Arash Hassantoufighi; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

3.  Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission.

Authors:  Elodie Ghedin; Edward C Holmes; Jay V DePasse; Lady Tatiana Pinilla; Adam Fitch; Marie-Eve Hamelin; Jesse Papenburg; Guy Boivin
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

4.  Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets.

Authors:  Matthew J Memoli; A Sally Davis; Kathleen Proudfoot; Daniel S Chertow; Rachel J Hrabal; Tyler Bristol; Jeffery K Taubenberger
Journal:  J Infect Dis       Date:  2010-12-20       Impact factor: 5.226

Review 5.  The role of viral, host, and secondary bacterial factors in influenza pathogenesis.

Authors:  John C Kash; Jeffery K Taubenberger
Journal:  Am J Pathol       Date:  2015-03-05       Impact factor: 4.307

6.  Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.

Authors:  Won-Young Kim; Gee Young Suh; Jin Won Huh; Sung-Han Kim; Min-ju Kim; Yun Seong Kim; Hye-Ryoun Kim; Yon Ju Ryu; Min Soo Han; Young Gwan Ko; Gyu Rak Chon; Kwan Ho Lee; Sang-Ho Choi; Sang-Bum Hong
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

7.  Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.

Authors:  Ashley N Brown; James J McSharry; Qingmei Weng; Jonathan R Adams; Robert Kulawy; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

8.  Detection of seasonal H3N2 influenza A virus by type-specific TaqMan minor groove binder probe assay.

Authors:  Ruixue Wang; Louis M Schwartzman; Matthew J Memoli; Jeffery K Taubenberger
Journal:  Diagn Microbiol Infect Dis       Date:  2011-03-22       Impact factor: 2.803

9.  Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.

Authors:  Bin Zhou; Victoria A Meliopoulos; Wei Wang; Xudong Lin; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Stacey Schultz-Cherry; David E Wentworth
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.

Authors:  Alireza Eshaghi; Sarah Shalhoub; Paul Rosenfeld; Aimin Li; Rachel R Higgins; Peter J Stogios; Alexei Savchenko; Nathalie Bastien; Yan Li; Coleman Rotstein; Jonathan B Gubbay
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.